Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants-Reference-Cited by-同舟云学术

Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants

Published:2023-05 Issue:5 Volume:42 Page:112443
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Qu Panke,Faraone Julia N.,Evans John P.,Zheng Yi-Min,Carlin Claire,Anghelina Mirela,Stevens Patrick,Fernandez Soledad,Jones Daniel,Panchal Ashish R.,Saif Linda J.,Oltz Eugene M.,Zhang Baoshan,Zhou Tongqing,Xu Kai,Gumina Richard J.,Liu Shan-Lu^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference49 articles.

1. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron;Shuai;Nature,2022

2. Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters;Yuan;Science,2022

3. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo;Hui;Nature,2022

4. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant;Suzuki;Nature,2022

5. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity;Meng;Nature,2022

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study;Vaccine: X;2024-10

2. AlphaFold2 Modeling and Molecular Dynamics Simulations of the Conformational Ensembles for the SARS-CoV-2 Spike Omicron JN.1, KP.2 and KP.3 Variants: Mutational Profiling of Binding Energetics Reveals Epistatic Drivers of the ACE2 Affinity and Escape Hotspots of Antibody Resistance;Viruses;2024-09-13

3. Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023;Eurosurveillance;2024-09-12

4. Neutralization and Stability of JN.1-derived LB.1, KP.2.3, KP.3 and KP.3.1.1 Subvariants;2024-09-05

5. Long-Term Immunity against SARS-CoV-2 Wild-Type and Omicron XBB.1.5 in Indonesian Residents after Vaccination and Infection;Antibodies;2024-09-02